Know Cancer

or
forgot password

A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma


Phase 3
18 Years
75 Years
Not Enrolling
Both
Non-Hodgkin's Lymphoma

Thank you

Trial Information

A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma


Inclusion Criteria:



- adult patients >=18 years of age;

- advanced, low-grade non-Hodgkin's and mantle cell lymphoma.

Exclusion Criteria:

- possibility of curative radiation therapy;

- secondary NHL;

- participation in another clinical trial eg with cytostatic chemotherapy or cytokines;

- concomitant diseases and/or restricted organ function precluding therapy according to
the study protocol.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Clinical response (complete or partial remission).

Outcome Time Frame:

After 8 months of treatment

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

Germany: Paul-Ehrlich-Institut

Study ID:

M39023

NCT ID:

NCT00269113

Start Date:

September 1998

Completion Date:

April 2009

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Mantle-Cell

Name

Location